论文部分内容阅读
目的:分析P-Akt和C-erbB-2蛋白表达水平与乳腺癌患者运用新辅助化疗治疗效果的关系。方法:选取2015年10月-2016年6月我院运用新辅助化疗结合手术治疗乳腺癌的患者80例。用免疫学方法对80例患者进行P-Akt和C-erbB-2蛋白表达水平检测;其次对乳腺癌患者的癌细胞死亡值进行标记,统一归纳汇总后,研究两者之间的联系,并采用TA和TAC两种新辅助化疗方案治疗。结果:有淋巴结转移患者的P-Akt和C-erbB-2蛋白表达阳性率为82.99%,无淋巴结转移患者的P-Akt和C-erbB-2蛋白表达阳性率为30.30%,前者明显高于后者;采用TA新辅助化疗方案治疗患者的化疗有效率为65.79%,TAC方案化疗有效率为73.81%,两者不具有统计学意义(P>0.05);P-Akt和C-erbB-2蛋白表达水平化疗前越高,乳腺癌患者的癌细胞死亡值化疗后就越低,反之则越高。结论:P-Akt和C-erbB-2蛋白表达水平和癌细胞死亡值,两者之间呈负相关关系,高水平的P-Akt和C-erbB-2蛋白表达会降低化疗的效果。
Objective: To analyze the relationship between the expression of P-Akt and C-erbB-2 protein and the effect of neoadjuvant chemotherapy in breast cancer patients. Methods: From October 2015 to June 2016, 80 cases of breast cancer were treated with neoadjuvant chemotherapy in our hospital. Immunohistochemistry was used to detect the expression of P-Akt and C-erbB-2 protein in 80 patients. Secondly, the death of breast cancer patients were marked with the cancer cell death values, and then the relationship between the two was studied. Treatment with TA and TAC two neoadjuvant chemotherapy regimens. Results: The positive rates of P-Akt and C-erbB-2 in patients with lymph node metastasis were 82.99%, while the positive rates of P-Akt and C-erbB-2 in patients without lymph node metastasis were 30.30% In the latter group, the effective rate of chemotherapy with TA neoadjuvant chemotherapy was 65.79% and that of TAC with chemotherapy was 73.81%, both of which were not statistically significant (P> 0.05); P-Akt and C-erbB-2 The higher the protein expression level before chemotherapy, the lower the death rate of cancer cells in breast cancer patients after chemotherapy, and vice versa. CONCLUSION: There is a negative correlation between the expression of P-Akt and C-erbB-2 protein and the death of cancer cells. High levels of P-Akt and C-erbB-2 protein may reduce the effect of chemotherapy.